Skip to content
sellWeak

Michael C Donegan sold $6,988 of TXMD

Prin. Fin. and Acctg. Officer at TherapeuticsMD, Inc.. 1,309 shares at an average of $5.34, traded Jan 23, 2023, filed Jan 25, 2023.

Warning score
5
Value
$6,988
1,309 shares
Holdings after
7,610
-15% from before
From 52-week low
+157%
low $2.07, close $5.32
From 52-week high
-76%
high $22.00, as of Jan 23, 2023

Score components

  • Role
    Officer
    +15
  • Trade size
    $7k at market
    0
  • Share of holdings sold
    Sold 15% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

TXMDOct 13, 2026 · close 1.96
Since filing Jan 25, 2023: -62.4%SPY +103.7% · excess -166.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001209191-23-004871, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 23, 2023MOption exercise
Common Stock
+380$0.00$04,934Jan 25, 2023
Jan 23, 2023MOption exercise
Common Stock
+1,066$0.00$06,000Jan 25, 2023
Jan 23, 2023MOption exercise
Common Stock
+519$0.00$06,519Jan 25, 2023
Jan 23, 2023MOption exercise
Common Stock
+2,400$0.00$08,919Jan 25, 2023
Jan 23, 2023SOpen-market sale
Common Stock
-1,302$5.34$6,9507,617Jan 25, 2023
Jan 24, 2023SOpen-market sale
Common Stock
-7$5.31$377,610Jan 25, 2023
Jan 23, 2023MOption exercise
Restricted Stock Unitsderivative
-380$0.00$00Jan 25, 2023
Jan 23, 2023MOption exercise
Restricted Stock Unitsderivative
-1,066$0.00$00Jan 25, 2023
Jan 23, 2023MOption exercise
Restricted Stock Unitsderivative
-519$0.00$00Jan 25, 2023
Jan 23, 2023MOption exercise
Restricted Stock Unitsderivative
-2,400$0.00$00Jan 25, 2023

Related signals

Other insiders at TherapeuticsMD, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
TXMDbuy
TherapeuticsMD, Inc.
Tommy G Thompson
director
$14k
8,400 shares
+57%
33Weak
TXMDbuy 2
TherapeuticsMD, Inc.
Marlan D Walker
Chief Executive Officer
$489
490 shares
+1%
23Weak
TXMDbuy 2
TherapeuticsMD, Inc.
Tommy G Thompson
director
$326
325 shares
+2%
33Weak
TXMDbuy 2
TherapeuticsMD, Inc.
Marlan D Walker
Chief Executive Officer
$1,994
2,303 shares
+3%
31Weak
TXMDbuy
TherapeuticsMD, Inc.
Cooper C. Collins
director
$7,099
4,094 shares
+9%
23Weak
TXMDbuy
TherapeuticsMD, Inc.
Cooper C. Collins
director
$2,039
1,200 shares
+3%
21Weak
TXMDsell
TherapeuticsMD, Inc.
Marlan D Walker
Chief Executive Officer
$44k
19,050 shares
-23%
5Weak
TXMDsell
TherapeuticsMD, Inc.
Michael C Donegan
Prin. Fin. and Acctg. Officer
$8,621
1,697 shares
-13%
24Weak
TXMDbuy
TherapeuticsMD, Inc.
Rubric Capital Management LP
owner
$90k
14,825 shares
+1%
30Weak
TXMDsell 5
TherapeuticsMD, Inc.
Brian Bernick
Co-Chief Executive Officer
$6,621
1,255 shares
-24%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael C Donegan sold $6,988 of TXMD | InsiderTell